Phone: (719) 264-6250    email:    Sign In | User Pages

Assays You Can Trust. Innovative Expertise You Can Count On.

Contract Services


Hepatotoxicity Contract Services

We are in the process of updating this page 



The drug development pipeline and how HepatoGlo-Tox HT can be used at different stage of the pipeline

Click image for larger view


As an organ that is primarily involved in detoxification, the liver represents a particularly important target for potential toxicity. Drug-induced liver toxicity (DILI) is the most common cause of market drug withdrawals. Hepatotoxicity can result from cellular and mitochondrial damage, oxidative stress and genotoxicity to mention but a few. In addition, drug-drug interactions (DDI) as a result of induction or inhibition of cytochrome P450 enzymes can play a significant role potential toxicity.


Various in vitro liver models have been developed to understand how the liver and, in particular, hepatocytes, function and respond to insults. These models include perfused organs, liver slices, three-dimensional matrix bioreactors and static culture systems. Consistant with its other in vitro toxicity testing platforms, HemoGenix® has deployed its ATP bioluminescence technology to hepatotoxicity applications by developing the HepatoGlo™-Tox HT Platform with high-performance HepatoGro™ Medium.


Benefits of Using HeptoGlo™-Tox HT for In Vitro Hepatotoxicity Testing
  • Hepatocytes produce high concentrations of intracellular ATP (iATP) due to their high metabolic activity. Changes in iATP concentration directly correlate with cellular and mitochondrial integrity and cytotoxicity.
  • Both primary and iPS-derived hepatocytes can be used with HepatoGlo™-Tox HT.
  • HepatoGlo™-Tox HT incorporates a validated ATP bioluminescence readout to measure hepatotoxicity.
  • HepatoGlo™-Tox HT is a calibrated and standardized assay platform that allows results to be directly compared between different drugs, hepatocyte sources and species over time.
  • High-throughput capability using 96- or 384-well plate formats allows ADME-Tox drug or compound screening, thereby significantly reducing unexpected results during pre-clinical testing.
  • Incorporates specialized HepatoGro™ medium and culture protocols.
  • 2D and 3D hepatotoxicity models available.
  • Hepatotoxicity contract studies can be performed using different oxygen tensions that simulate different conditions and areas in the liver.
  • Available for adherent or non-adherent cell populations.
  • HepatoGlo™-Tox HT can be used to investigate cellular drug-drug interactions or multiplexed with CYP450 studies at the sub-cellular level.
  • Incorporates the most sensitive ATP bioluminescence readout available.
  • Incubation times: Usually 4-24 hours.
  • Turnaround time: Usually within 1-3 days.
  • Validated assay readout according to FDA Bioanalytical Method Guidelines.
  • Designed for multiplexing with other assays using the same sample thereby allowing multiple and liver-specific readouts.
  • A 3Rs Assay Platform-Helps Reduction, Refinement, Replacement of animal testing.


 Hepatocyte Sources for HepatoGlo™-Tox HT

  • Fresh
  • Cryopreserved
  • Male
  • Female
  • Individual or pooled
  • ES- and/or iPS-derived
  • Hepatocyte cell lines e.g. HepG2
 Species Available for Use with HepatoGlo™-Tox HT

  • Human
  • Non-human primate
  • Dog
  • Rat
  • Mouse
 Assays that can be Multiplexed with HepatoGlo™-Tox HT
  • Cytochrome P450 enzyme assays.
  • Cellular drug-drug interaction assays.
  • Membrane integrity: LDH or PI dye exclusion.
  • Apoptosis: Biochemical caspase detection.
  • Mitochondrial dysfunction: Mitochondrial ToxGlo™
  • Glutathione Assay (GSH): Oxidative stress.
  • OxyFLOW™: Oxidative DNA damage.